Targeted Oncology· @TargetedOnc · X·· 13 小时前评分70
正文 · 原文
What a remarkable day at #ESMO26 in Madrid!
INTerpath-001, VOLGA, DeLLphi-305 & CheckMate 8HW delivered major advances. COMPANION-002 sparked important debate on PFS and OS.
Celebrate progress. Challenge evidence. Keep patients first.
Thank you, @TargetedOnc!
109 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA1按 Presidential Symposium I 对上
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgINTerpath-001
https://esmocongress.esmo.org来源：Targeted Oncology · x.com